Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder

IF 2.7 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Opinion on Emerging Drugs Pub Date : 2024-04-29 DOI:10.1080/14728214.2024.2345645

Elliot Hampsey, Luke Jelen, Allan H. Young

引用次数: 0

Abstract

Major depression is a common, disabling mental health condition associated with the highest disease burden for any neuropsychiatric disorder worldwide according to the WHO. Due to the imperfect eff...

查看原文本刊更多论文

Aticaprant：（一种κ-阿片受体拮抗剂），用于治疗重度抑郁症

根据世界卫生组织的数据，重度抑郁症是一种常见的致残性精神疾病，是全球所有神经精神疾病中疾病负担最重的一种。由于治疗效果不尽如人意...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Emerging Drugs 医学-药学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.